Partnering to enable
next-generation molecular diagnostics.
Thank you for connecting with us at recent partnering conferences and investor meetings.
We are currently engaging strategic partners and investors to advance our extraction-free PCR platform.
WHAT WE DO
Transformative Biotech is transforming PCR testing for infectious diseases @ANYWHERE™. Our patented DirectAmp™ direct-to-PCR platform eliminates the nucleic-acid extraction step from molecular testing, delivering faster, more cost-effective results without compromising gold-standard PCR accuracy. Clinically proven on more than 590,000 patient samples, the platform has demonstrated proof of concept across respiratory infections (Flu, COVID-19) and sexually transmitted infections (chlamydia, gonorrhea).
We are raising a Seed round to advance 510(k)‑enabling studies, expand independent infectious‑disease validation, and establish OEM partnerships that embed our chemistry into decentralized PCR workflows.
In parallel, we are developing the @ANYWHERE™ handheld, smartphone-powered device that combines our direct-to-PCR chemistry with advanced microfluidics and acoustic mixing to enable rapid, accurate, affordable testing outside the lab.
WHY PARTNER WITH TRANSFORMATIVE BIOTECH
- Platform-enabling technologies compatible with existing PCR and emerging molecular workflows
- Strong and growing IP portfolio, including landmark U.S. Patent #12,344,889
- Clear commercialization pathways from RUO reagent sales through IVD and device licensing
WHERE TO MEET US
Presenting and meeting at various leading life sciences conferences throughout 2026. Reach out below if you’d like to connect!
KEY DOCUMENTS
LSI USA '26 | KEVIN KRAUS, CEO
CONNECT WITH US
Met us at a conference this year? We’d love to connect. Please note: no solicitations.
LEARN MORE
Learn more about Transformative Biotech at transformative-bio.com.